BRPI0816554B8 - compostos como antagonistas de receptores de adenosina a1 - Google Patents

compostos como antagonistas de receptores de adenosina a1

Info

Publication number
BRPI0816554B8
BRPI0816554B8 BRPI0816554A BRPI0816554A BRPI0816554B8 BR PI0816554 B8 BRPI0816554 B8 BR PI0816554B8 BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 B8 BRPI0816554 B8 BR PI0816554B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
straight
branched
group
halogen atoms
Prior art date
Application number
BRPI0816554A
Other languages
English (en)
Inventor
Gonzalez Lio Lyhen
Alberto Camacho Gomez Juan
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of BRPI0816554A2 publication Critical patent/BRPI0816554A2/pt
Publication of BRPI0816554B1 publication Critical patent/BRPI0816554B1/pt
Publication of BRPI0816554B8 publication Critical patent/BRPI0816554B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Compostos como antagonistas de receptores de adenosina A1. Estes compostos correspondem à fórmula (I), onde: R1 representa um grupo de arila ou heteroarila opcionalmente substituído por um ou mais substituintes selecionados de um grupo composto por átomos de halogênio, retos ou ramificados, substituídos opcionalmente por aquila, cicloalquila, hidroxi inferior retos ou ramificados, opcionalmente substitídos opcionalmente substituídos por alcóxico, cianureto, ou -C02R', onde R' representa um átomo de hidrogênio ou um grupo de alquila inferior substituido opcionalmente, reto ou ramificad; R representa um grupo selecionado de: a) um grupo de alquila inferior reto ou ramificado substituído por um ou mais grupos carbocílicos; (-COOH) e opcionalmente substituído por um ou mais grupos carboxilicos (-COOH) e opcionalmente substituído por um ou mais átomos de halogênio b) um grupo de cicloalquila substituido por um ou mais grupos carboxilicos (-COOH) e opcionalmente substituído por um ou mais átomos de halogênio; c) um grupo de alquilacicloalquila ou cicloalquila alquila reto ou tamificado substituído por um ou mais grupos carboxílicos (-COOH) e opcionalmente por um mais átomos de halogênio. Fórmula (I)
BRPI0816554A 2007-10-02 2008-09-30 compostos como antagonistas de receptores de adenosina a1 BRPI0816554B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702643 2007-10-02
ES200702643A ES2331220B1 (es) 2007-10-02 2007-10-02 Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
PCT/IB2008/002556 WO2009044250A1 (en) 2007-10-02 2008-09-30 New compounds as adenosine a1 receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0816554A2 BRPI0816554A2 (pt) 2015-11-24
BRPI0816554B1 BRPI0816554B1 (pt) 2019-04-09
BRPI0816554B8 true BRPI0816554B8 (pt) 2022-08-30

Family

ID=40303525

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816554A BRPI0816554B8 (pt) 2007-10-02 2008-09-30 compostos como antagonistas de receptores de adenosina a1

Country Status (20)

Country Link
US (1) US8410282B2 (pt)
EP (1) EP2197860B1 (pt)
JP (1) JP5463592B2 (pt)
KR (1) KR101312198B1 (pt)
CN (1) CN101835766B (pt)
AT (1) ATE510829T1 (pt)
AU (1) AU2008306553B2 (pt)
BR (1) BRPI0816554B8 (pt)
CA (1) CA2700526C (pt)
CY (1) CY1112079T1 (pt)
DK (1) DK2197860T3 (pt)
EA (1) EA022473B1 (pt)
ES (2) ES2331220B1 (pt)
HR (1) HRP20110557T1 (pt)
MX (1) MX2010003576A (pt)
PL (1) PL2197860T3 (pt)
PT (1) PT2197860E (pt)
SI (1) SI2197860T1 (pt)
WO (1) WO2009044250A1 (pt)
ZA (1) ZA201002139B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
US9518033B2 (en) 2013-01-03 2016-12-13 Council Of Scientific & Industrial Research (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles as A2AR antagonist and process for preparation thereof
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
ES2578363B1 (es) * 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska
CN107739350B (zh) * 2017-09-26 2020-12-22 天津大学 一种合成2-氨基噻唑衍生物的方法
EP3882240A1 (en) * 2020-03-16 2021-09-22 Palobiofarma, S.L. Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
EP1466912B1 (en) * 2002-01-18 2013-04-24 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina

Also Published As

Publication number Publication date
ES2366075T3 (es) 2011-10-17
DK2197860T3 (da) 2011-08-15
CY1112079T1 (el) 2015-11-04
BRPI0816554A2 (pt) 2015-11-24
CN101835766A (zh) 2010-09-15
EP2197860A1 (en) 2010-06-23
ES2331220B1 (es) 2010-09-23
WO2009044250A1 (en) 2009-04-09
HRP20110557T1 (hr) 2011-09-30
BRPI0816554B1 (pt) 2019-04-09
JP2010540615A (ja) 2010-12-24
EP2197860B1 (en) 2011-05-25
SI2197860T1 (sl) 2011-09-30
CN101835766B (zh) 2013-09-25
AU2008306553B2 (en) 2011-06-09
EA201000393A1 (ru) 2010-08-30
AU2008306553A1 (en) 2009-04-09
JP5463592B2 (ja) 2014-04-09
US20100311703A1 (en) 2010-12-09
CA2700526A1 (en) 2009-04-09
ZA201002139B (en) 2011-06-29
MX2010003576A (es) 2010-04-22
PL2197860T3 (pl) 2011-09-30
KR20100058653A (ko) 2010-06-03
ES2331220A1 (es) 2009-12-23
EA022473B1 (ru) 2016-01-29
US8410282B2 (en) 2013-04-02
PT2197860E (pt) 2011-08-26
ATE510829T1 (de) 2011-06-15
CA2700526C (en) 2014-03-18
KR101312198B1 (ko) 2013-09-27

Similar Documents

Publication Publication Date Title
BRPI0816554A2 (pt) compostos como antagonistas de receptores de adenosina a1.
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
UY32074A (es) Compuestos de pirrol
CR11021A (es) Derivados de quinolina como fungicidas
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
UY32481A (es) Derivados de benzofurano
MY152281A (en) 4-pyrimidinesulfamide derivative
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
MY161134A (en) Piperazine compound having a pgds inhibitory effect
MA32296B1 (fr) Derives de piperidine 3,4-substitues comme inhibiteurs de la renine
GT200700074A (es) Fungicidas
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
HK1151797A1 (pt)
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
CO6300944A2 (es) Derivado de hidroxi-quinoxalin-carboxamida
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
EA201170606A1 (ru) Феназопиридиновые соединения
WO2009130469A8 (en) Dna-pk inhibitors
BR112012017126A2 (pt) derivados de aminoalquilpirimidina como antagonistas de receptor de h4 de histamina
PH12014502845A1 (en) Novel cholecystokinin receptor ligands
EA201101325A1 (ru) ПРОИЗВОДНЫЕ ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА α7 nAChR
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
TN2011000094A1 (en) Pyrrole compounds
TW200743647A (en) Fluorene derivatives with thiophene moiety and method for forming the same
TH126084B (th) อนุพันธ์ 5-ฟลูออโร-2-ออกโซพิริมิดีน-1(2h)-คาร์บอกซิเลท

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2518 DE 09/04/2019 QUANTO AO INVENTOR.